Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

Objective: Our aim was to assess the role of the body mass index (BMI) in the clinical response to systemic treatment for psoriasis. Methods: A nationwide cohort study of patients receiving a new systemic treatment for plaque psoriasis at reference centres in Italy was conducted. Information was gathered through a web-based electronic form. Patients being maintained on the same medication and with data available at 8 and 16 weeks by March 31, 2007, were eligible. The outcome was a reduction in the Psoriasis Area Severity Index (PASI) of at least 75% at follow-up compared to baseline (PASI-75). Results: Out of 8,072 patients enrolled, 2,368 were eligible and analysable at 8 weeks and 2,042 at 16 weeks. PASI-75 was achieved by 819 patients (34.5%) at 8 weeks and 1,034 (50.6%) at 16 weeks. The proportion steadily decreased with increased values of BMI. Compared to normal weight (BMI = 20–24) the adjusted odds ratio for achieving PASI-75 in obese patients was 0.73 (95% CI = 0.58–0.93) at 8 weeks and 0.62 (95% CI = 0.49–0.79) at 16 weeks. The impact of the BMI did not show remarkable variations according to the drug prescribed at entry. Conclusion: The BMI affects the early clinical response to systemic treatment for psoriasis.

[1]  Michael Hinckley,et al.  Impact of obesity and smoking on psoriasis presentation and management. , 2005, Archives of dermatology.

[2]  P. Venge,et al.  A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. , 1983, Acta dermato-venereologica.

[3]  B. Strober,et al.  Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review , 2007, The British journal of dermatology.

[4]  A. J. van der Lely,et al.  Chronic inflammation in psoriasis and obesity: implications for therapy. , 2006, Medical hypotheses.

[5]  Consuelo Huerta,et al.  Incidence and risk factors for psoriasis in the general population. , 2007, Archives of dermatology.

[6]  L. Naldi,et al.  Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. , 2005, The Journal of investigative dermatology.

[7]  N. Breslow,et al.  The analysis of case-control studies , 1980 .

[8]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[9]  H. Yasuda,et al.  Prognostic Factor Analysis for Plaque Psoriasis , 2005, Dermatology.

[10]  H. Williams,et al.  Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. , 2003, The Journal of investigative dermatology.

[11]  A. Kimball,et al.  The Psychosocial Burden of Psoriasis , 2005, American journal of clinical dermatology.

[12]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[13]  Hyon K. Choi,et al.  Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.

[14]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[15]  M. Neves,et al.  Remission of Psoriasis after Open Gastric Bypass , 2006, Obesity surgery.

[16]  R. Dellavalle,et al.  Do smoking, obesity, and stress cause psoriasis? , 2005, The Journal of investigative dermatology.

[17]  A. Kimball,et al.  Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001–2002 , 2008, Dermatology.

[18]  R. Stern,et al.  Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. , 2006, The Journal of investigative dermatology.

[19]  O. Førre,et al.  Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis , 1991, The Lancet.

[20]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[21]  B. Lindegård.  Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. , 1986, Dermatologica.

[22]  N. Breslow,et al.  Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .

[23]  J. Callen,et al.  Obesity, smoking, and psoriasis. , 2006, JAMA.

[24]  N. Bukan,et al.  Circulating concentrations of adiponectin and tumor necrosis factor-α in gestational diabetes mellitus , 2007 .

[25]  P. Boffetta,et al.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. , 2001, The Journal of investigative dermatology.

[26]  T. Yamakawa,et al.  T lymphopaenia in relation to body mass index and TNF‐α in human obesity: adequate weight reduction can be corrective , 2001, Clinical endocrinology.

[27]  T. Pollmächer,et al.  TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. , 2006, European cytokine network.

[28]  E. Christophers,et al.  Disease concomitance in psoriasis. , 1995, Journal of American Academy of Dermatology.

[29]  L. Naldi,et al.  Epidemiology of psoriasis. , 2004, Current drug targets. Inflammation and allergy.

[30]  E. Gehan,et al.  Estimation of human body surface area from height and weight. , 1970, Cancer chemotherapy reports.

[31]  J. Meyerovitch,et al.  Association between Psoriasis and the Metabolic Syndrome , 2008, Dermatology.

[32]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2006, Journal of the American Academy of Dermatology.

[33]  R. Stern.  A promising step forward in psoriasis therapy. , 2003, JAMA.